(IQV) IQVIA Holdings - Overview

Exchange: NYSE • Country: United States • Currency: USD • Type: Common Stock • ISIN: US46266C1053

Stock: Clinical Research, Analytics, Consulting, Trial Support, Outsourcing

Total Rating 26

Risk 62

Buy Signal -0.39

Diagnostics & Research » Life Sciences Tools & Services
Age: 12.8y

Market Cap: 39,378m
Avg Trading Vol: 315M USD

ATR: 5.06%
Peers RS (IBD): 18.18

EPS (Earnings per Share)

EPS CAGR: -47.22%
EPS Trend: -46.3%

Last SUE: -4.00
Qual. Beats: 0

Revenue

Rev. CAGR: 3.25%
Rev. Trend: 91.8%

Last SUE: 0.69
Qual. Beats: 0

Risk 5d forecast
Volatility	93.3%
Relative Tail Risk	-9.48%

Reward TTM
Sharpe Ratio	-0.17
Alpha	-25.69

Character TTM
Beta	1.114
Beta Downside	1.155

Drawdowns 3y
Max DD	47.12%
CAGR/Max DD	-0.12

Description: IQV IQVIA Holdings December 17, 2025

IQVIA Holdings Inc. (NYSE:IQV) delivers end-to-end data, analytics, and clinical services to life-science and health-care companies across the Americas, Europe, Africa, and Asia-Pacific, organized into three operating segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Key recent metrics: FY 2023 revenue reached $13.1 billion, up 5 % YoY, driven by a 12 % rise in the Real-World Evidence (RWE) platform and a 9 % increase in contract sales services. The company posted an adjusted operating margin of 13.2 % and generated $1.8 billion of free cash flow, supporting its $2.5 billion backlog of multi-year contracts. Core sector drivers include accelerating pharmaceutical R&D spend (projected CAGR ≈ 7 % through 2028), the industry’s shift toward decentralized clinical trials, and heightened regulator demand for real-world data to inform drug approvals.

For deeper valuation metrics and scenario analysis, you might find ValueRay’s IQV page worth a look.

Piotroski VR‑10 (Strict, 0-10) 7.0

Net Income: 1.28b TTM > 0 and > 6% of Revenue
FCF/TA: 0.09 > 0.02 and ΔFCF/TA 1.98 > 1.0
NWC/Revenue: -15.90% < 20% (prev -8.88%; Δ -7.02% < -1%)
CFO/TA 0.10 > 3% & CFO 2.80b > Net Income 1.28b
Net Debt (13.38b) to EBITDA (3.44b): 3.89 < 3
Current Ratio: 0.70 > 1.5 & < 3
Outstanding Shares: last quarter (171.7m) vs 12m ago -6.79% < -2%
Gross Margin: 33.78% > 18% (prev 0.33%; Δ 3344 % > 0.5%)
Asset Turnover: 56.89% > 50% (prev 56.35%; Δ 0.55% > 0%)
Interest Coverage Ratio: 3.26 > 6 (EBITDA TTM 3.44b / Interest Expense TTM 707.0m)

Altman Z'' 1.04

A: -0.09 (Total Current Assets 5.98b - Total Current Liabilities 8.51b) / Total Assets 28.73b
B: 0.24 (Retained Earnings 6.91b / Total Assets 28.73b)
C: 0.08 (EBIT TTM 2.31b / Avg Total Assets 27.95b)
D: 0.27 (Book Value of Equity 5.99b / Total Liabilities 22.44b)
Altman-Z'' Score: 1.04 = BB

Beneish M -3.08

DSRI: 0.98 (Receivables 3.31b/3.25b, Revenue 15.90b/15.31b)
GMI: 0.99 (GM 33.78% / 33.42%)
AQI: 1.00 (AQ_t 0.76 / AQ_t-1 0.76)
SGI: 1.04 (Revenue 15.90b / 15.31b)
TATA: -0.05 (NI 1.28b - CFO 2.80b) / TA 28.73b)
Beneish M-Score: -3.08 (Cap -4..+1) = AA

What is the price of IQV shares?

As of February 08, 2026, the stock is trading at USD 187.49 with a total of 3,443,048 shares traded.
Over the past week, the price has changed by -18.54%, over one month by -22.05%, over three months by -11.08% and over the past year by -10.70%.

Is IQV a buy, sell or hold?

IQVIA Holdings has received a consensus analysts rating of 4.30. Therefore, it is recommended to buy IQV.

StrongBuy: 14
Buy: 2
Hold: 7
Sell: 0
StrongSell: 0

What are the forecasts/targets for the IQV price?

Issuer	Target	Up/Down from current
Wallstreet Target Price	261.2	39.3%
Analysts Target Price	261.2	39.3%
ValueRay Target Price	181.4	-3.3%

IQV Fundamental Data Overview February 04, 2026

P/E Trailing = 31.632
P/E Forward = 17.9856
P/S = 2.476
P/B = 6.514
P/EG = 0.9992
Revenue TTM = 15.90b USD
EBIT TTM = 2.31b USD
EBITDA TTM = 3.44b USD
Long Term Debt = 12.79b USD (from longTermDebt, last quarter)
Short Term Debt = 2.16b USD (from shortTermDebt, last quarter)
Debt = 15.19b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 13.38b USD (from netDebt column, last quarter)
Enterprise Value = 52.75b USD (39.38b + Debt 15.19b - CCE 1.81b)
Interest Coverage Ratio = 3.26 (Ebit TTM 2.31b / Interest Expense TTM 707.0m)
EV/FCF = 19.98x (Enterprise Value 52.75b / FCF TTM 2.64b)
FCF Yield = 5.00% (FCF TTM 2.64b / Enterprise Value 52.75b)
FCF Margin = 16.60% (FCF TTM 2.64b / Revenue TTM 15.90b)
Net Margin = 8.07% (Net Income TTM 1.28b / Revenue TTM 15.90b)
Gross Margin = 33.78% ((Revenue TTM 15.90b - Cost of Revenue TTM 10.53b) / Revenue TTM)
Gross Margin QoQ = 33.49% (prev 32.94%)
Tobins Q-Ratio = 1.84 (Enterprise Value 52.75b / Total Assets 28.73b)
Interest Expense / Debt = 1.24% (Interest Expense 189.0m / Debt 15.19b)
Taxrate = 18.63% (76.0m / 408.0m)
NOPAT = 1.88b (EBIT 2.31b * (1 - 18.63%))
Current Ratio = 0.70 (Total Current Assets 5.98b / Total Current Liabilities 8.51b)
Debt / Equity = 2.47 (Debt 15.19b / totalStockholderEquity, last quarter 6.16b)
Debt / EBITDA = 3.89 (Net Debt 13.38b / EBITDA 3.44b)
Debt / FCF = 5.07 (Net Debt 13.38b / FCF TTM 2.64b)
Total Stockholder Equity = 6.00b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.59% (Net Income 1.28b / Total Assets 28.73b)
RoE = 21.40% (Net Income TTM 1.28b / Total Stockholder Equity 6.00b)
RoCE = 12.27% (EBIT 2.31b / Capital Employed (Equity 6.00b + L.T.Debt 12.79b))
RoIC = 9.07% (NOPAT 1.88b / Invested Capital 20.69b)
WACC = 7.51% (E(39.38b)/V(54.57b) * Re(10.02%) + D(15.19b)/V(54.57b) * Rd(1.24%) * (1-Tc(0.19)))
Discount Rate = 10.02% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -3.48%
[DCF Debug] Terminal Value 80.92% ; FCFF base≈2.37b ; Y1≈2.55b ; Y5≈3.14b
Fair Price DCF = 275.9 (EV 60.36b - Net Debt 13.38b = Equity 46.98b / Shares 170.3m; r=7.51% [WACC]; 5y FCF grow 8.85% → 2.90% )
EPS Correlation: -46.33 | EPS CAGR: -47.22% | SUE: -4.0 | # QB: 0
Revenue Correlation: 91.76 | Revenue CAGR: 3.25% | SUE: 0.69 | # QB: 0
EPS next Quarter (2026-03-31): EPS=2.96 | Chg30d=+0.002 | Revisions Net=+1 | Analysts=14
EPS next Year (2026-12-31): EPS=12.96 | Chg30d=+0.023 | Revisions Net=+0 | Growth EPS=+8.7% | Growth Revenue=+5.5%

Additional Sources for IQV Stock

News: Wall Street Journal | Benzinga | Yahoo Finance
Fund Manager Positions: Dataroma | Stockcircle